Tech Company Financing Transactions
Breath Therapeutics Funding Round
On 3/9/2017, Breath Therapeutics announced $45.8 million in Series A funding from GIMV, Sofinnova Ventures and Gilde Healthcare Partners.
Transaction Overview
Company Name
Announced On
3/9/2017
Transaction Type
Venture Equity
Amount
$45,803,107
Round
Series A
Investors
GIMV (Lead Investor) (Karl Nägler)
Sofinnova Ventures (Lead Investor) (Graziano Seghezzi)
Gilde Healthcare Partners (Arthur Franken)
Proceeds Purpose
The company intends to use the funds to conduct phase 3 trials in Europe and the US, respectively, submit for marketing approval, and prepare for commercialization.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Frankfurt, 60326
Germany
Frankfurt, 60326
Germany
Phone
Undisclosed
Website
Email Address
Overview
Breath Therapeutics' lead programme is a first-in-class therapeutic/med-tech device combination to treat the Bronchiolitis Obliterans Syndrome (BOS), a life-threatening disease that occurs after 65% of lung transplantations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jens Stegemann
Chief Financial Officer
Gerhard Boerner
Chief Financial Officer
Anne Burger
Chief Operating Officer
Oliver Denk
Browse more venture capital transactions:
Prev: 3/9/2017: Virta Health venture capital transaction
Next: 3/9/2017: LoopMe venture capital transaction
Share this article
About Database of VC Transactions
We document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs